Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
News|Articles|March 31, 2026
Top FDA news in women's health you missed in Q1 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.
Advertisement
Advertisement
The first quarter of 2026 is all but in the books, with several noteworthy updates from the United States FDA having taken place. From federal agency feedback on testosterone therapy to updated labels for multiple menopausal hormone therapies, there was a lot to keep track of in women’s health in Q1.
Related to this article
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Advertisement
Advertisement